
Quarterly ResultAug 6, 2026, 04:40 PM
Lyell Immunopharma Q2 Net Loss $(44.8)M; YTD Loss $(68.9)M; Raises $50M
AI Summary
Lyell Immunopharma reported a net loss of $(44.8) million for the second quarter of 2026, an increase from $(42.7) million in the prior year's quarter. However, the net loss for the six months ended June 30, 2026, improved to $(68.9) million compared to $(94.9) million in the same period of 2025. The company also raised $50.0 million from a securities purchase agreement equity issuance and $1.7 million from an at-the-market offering during the first half of 2026, contributing to a net increase in cash and cash equivalents. A clinical milestone for 1.1 million shares related to the LYL273 license was achieved.
Key Highlights
- Net loss for Q2 2026 was $(44.8) million, up from $(42.7) million in Q2 2025.
- Net loss for H1 2026 improved to $(68.9) million from $(94.9) million in H1 2025.
- Research and development expenses for H1 2026 decreased to $76.1 million.
- Raised $50.0 million from equity issuance via securities purchase agreement.
- Raised $1.7 million from at-the-market offering.
- Net cash used in operating activities for H1 2026 was $(72.4) million.
- Cash and cash equivalents increased to $73.0 million as of June 30, 2026.
- A clinical milestone for 1.1 million shares related to LYL273 was achieved.
Price Impact
More from LYEL